A basic research to develop cancer peptide vaccine for transdermal immunization

2019 Fiscal Year Final Research Report

• Project/Area Number: 17K07229
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Tumor therapeutics
• Research Institution: Kurume University
• Principal Investigator: Waki Kayoko 久留米大学, 付置研究所, 助教 (40649597)
• Co-Investigator(Kenkyū-buntansha): 山田 亮 久留米大学, 付置研究所, 教授 (50158177)
• Project Period (FY): 2017-04-01 – 2020-03-31
• Keywords: がんペプチドワクチン / 経皮ワクチン

Outline of Final Research Achievements

This project aimed to develop transdermal cancer peptide vaccine without Floyd’s incomplete adjuvant using a mouse model. Lactic acid-based chemical peeling prior to peptide vaccination augmented the proliferation of peptide-specific T cells in the CFSE cell division assay. In addition, application of imiquimod cream at the vaccinated site following the vaccination significantly induced peptide specific cytotoxic T cells in IFN-gamma ELISPOT assay. These suggested the possibility of transdermal cancer peptide vaccine, which was patient-friendly.

Free Research Field

がん免疫

Academic Significance and Societal Importance of the Research Achievements

がんペプチドワクチンはがん抗原ペプチドをフロイント不完全アジュバントでエマルジョン化したワクチンを皮下投与するのが主流であるが、ワクチンの投与部位への長期残留と炎症反応が患者の大きな負担になっている。本研究で行った乳酸を用いた経皮がんペプチドワクチンが抗原特異的細胞傷害性T細胞を誘導できることから、患者にやさしい経皮がんペプチドワクチン療法の可能性を示唆している。